Literature DB >> 26516224

Principles of immunology and its nuances in the central nervous system.

Gavin P Dunn1, Hideho Okada1.   

Abstract

Cancer immunotherapy represents the biggest change in the cancer treatment landscape in the last several years. Indeed, the clinical successes in several cancer types have generated widespread enthusiasm that immune-based treatments may influence the management of patients with malignant brain tumors as well. A number of promising clinical trials in this area are currently ongoing in neuro-oncology, and a wave of additional efforts are sure to follow. However, the basic immunology underlying immunotherapy-and the nuances unique to the immunobiology in the central nervous system-is often not in the daily lexicon of the practicing neuro-oncologist and neurosurgeon. To this end, here we provide a timely and working overview of key principles of fundamental immunology as a pragmatic context for understanding where therapeutic efforts may act in the cellular dynamics of the immune response. Moreover, we review the issues of lymphatic drainage, antigen presentation, and the blood-brain barrier as considerations that are germane to thinking about immunity to tumors arising in the brain. Together, these topics will provide a foundation for the exciting efforts in immune-based treatments that will hopefully provide real benefit to brain tumor patients.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adaptive immunity; antigen presentation; blood-brain barrier; immunology; immunotherapy; innate immunity

Mesh:

Year:  2015        PMID: 26516224      PMCID: PMC4625893          DOI: 10.1093/neuonc/nov175

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  54 in total

Review 1.  Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain.

Authors:  Burkhard Becher; Ingo Bechmann; Melanie Greter
Journal:  J Mol Med (Berl)       Date:  2006-06-14       Impact factor: 4.599

Review 2.  How dying cells alert the immune system to danger.

Authors:  Hajime Kono; Kenneth L Rock
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

3.  Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.

Authors:  P B MEDAWAR
Journal:  Br J Exp Pathol       Date:  1948-02

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Glioblastoma stem-like cells give rise to tumour endothelium.

Authors:  Rong Wang; Kalyani Chadalavada; Jennifer Wilshire; Urszula Kowalik; Koos E Hovinga; Adam Geber; Boris Fligelman; Margaret Leversha; Cameron Brennan; Viviane Tabar
Journal:  Nature       Date:  2010-11-21       Impact factor: 49.962

Review 6.  Natural killer cell immune responses.

Authors:  Wayne M Yokoyama
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; James E Herndon; Denise Lally-Goss; Sharon McGehee-Norman; Alison Paolino; David A Reardon; Allan H Friedman; Henry S Friedman; Darell D Bigner
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

8.  Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.

Authors:  Ingo Bartholomäus; Naoto Kawakami; Francesca Odoardi; Christian Schläger; Djordje Miljkovic; Joachim W Ellwart; Wolfgang E F Klinkert; Cassandra Flügel-Koch; Thomas B Issekutz; Hartmut Wekerle; Alexander Flügel
Journal:  Nature       Date:  2009-10-14       Impact factor: 49.962

Review 9.  DCVax-Brain and DC vaccines in the treatment of GBM.

Authors:  Christopher J Wheeler; Keith L Black
Journal:  Expert Opin Investig Drugs       Date:  2009-04       Impact factor: 6.206

10.  Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.

Authors:  Mitsugu Fujita; Xinmei Zhu; Ryo Ueda; Kotaro Sasaki; Gary Kohanbash; Edward R Kastenhuber; Heather A McDonald; Gregory A Gibson; Simon C Watkins; Ravikumar Muthuswamy; Pawel Kalinski; Hideho Okada
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

View more
  14 in total

Review 1.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Authors:  David A Reardon; Duane A Mitchell
Journal:  Semin Immunopathol       Date:  2017-01-30       Impact factor: 9.623

2.  Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

Authors:  Tanner M Johanns; Jeffrey P Ward; Christopher A Miller; Courtney Wilson; Dale K Kobayashi; Diane Bender; Yujie Fu; Anton Alexandrov; Elaine R Mardis; Maxim N Artyomov; Robert D Schreiber; Gavin P Dunn
Journal:  Cancer Immunol Res       Date:  2016-10-31       Impact factor: 11.151

Review 3.  Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

Authors:  Gavin P Dunn; Timothy F Cloughesy; Marcela V Maus; Robert M Prins; David A Reardon; Adam M Sonabend
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

Review 4.  Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.

Authors:  Tanner M Johanns; Gavin P Dunn
Journal:  Cancer J       Date:  2017 Mar/Apr       Impact factor: 3.360

Review 5.  Immune checkpoint inhibitors in GBM.

Authors:  Eudocia Q Lee
Journal:  J Neurooncol       Date:  2021-10-01       Impact factor: 4.130

Review 6.  The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.

Authors:  Takahide Nejo; Abigail Mende; Hideho Okada
Journal:  Jpn J Clin Oncol       Date:  2020-10-22       Impact factor: 3.019

7.  Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

Authors:  Tanner M Johanns; Christopher A Miller; Ian G Dorward; Christina Tsien; Edward Chang; Arie Perry; Ravindra Uppaluri; Cole Ferguson; Robert E Schmidt; Sonika Dahiya; George Ansstas; Elaine R Mardis; Gavin P Dunn
Journal:  Cancer Discov       Date:  2016-09-28       Impact factor: 39.397

Review 8.  Is there a role for neoadjuvant anti-PD-1 therapies in glioma?

Authors:  Lu Sun; Thomas J Lai; Robert M Prins
Journal:  Curr Opin Neurol       Date:  2021-12-01       Impact factor: 5.710

Review 9.  Management of intracranial melanomas in the era of precision medicine.

Authors:  Grace J Young; Wenya Linda Bi; Winona W Wu; Tanner M Johanns; Gavin P Dunn; Ian F Dunn
Journal:  Oncotarget       Date:  2017-07-13

10.  Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice.

Authors:  Clément Ricard; Aurélie Tchoghandjian; Hervé Luche; Pierre Grenot; Dominique Figarella-Branger; Geneviève Rougon; Marie Malissen; Franck Debarbieux
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.